×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HOTH – hoth therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HOTH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/10
08:30 am
hoth
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
Low
Report
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
2/5
08:03 am
hoth
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
Medium
Report
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets
1/22
08:13 am
hoth
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
Medium
Report
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
1/21
08:13 am
hoth
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
Low
Report
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
1/15
08:17 am
hoth
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
Low
Report
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation
1/2
08:47 am
hoth
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform [Yahoo! Finance]
Medium
Report
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform [Yahoo! Finance]
1/2
08:13 am
hoth
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
Low
Report
Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform
12/16
04:37 pm
hoth
Hoth Therapeutics (NASDAQ:HOTH) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Hoth Therapeutics (NASDAQ:HOTH) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/16
08:05 am
hoth
Form 8-K Hoth Therapeutics, Inc. For: Jan 16
Low
Report
Form 8-K Hoth Therapeutics, Inc. For: Jan 16
12/5
06:03 am
hoth
Form EFFECT Hoth Therapeutics, Inc.
Low
Report
Form EFFECT Hoth Therapeutics, Inc.
11/17
06:00 am
hoth
Form S-3 Hoth Therapeutics, Inc.
Low
Report
Form S-3 Hoth Therapeutics, Inc.
11/13
01:03 pm
hoth
Form 424B5 Hoth Therapeutics, Inc.
Low
Report
Form 424B5 Hoth Therapeutics, Inc.
11/12
04:18 pm
hoth
Form 10-Q Hoth Therapeutics, Inc. For: Sep 30
Medium
Report
Form 10-Q Hoth Therapeutics, Inc. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Hoth Therapeutics Announces Agreement to Joint Development of a Self-Assembling Vaccine (SAV) for the Potential Treatment of the Coronavirus (COVID-19)
38.5%
4/22 Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate 30.8%
2/4 Hoth Initiates Preclinical Gene Therapy Program with NC State for the Treatment of Asthma and Allergic Inflammation 16.0%
11/26 Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy 15.9%
6/27 Hoth Therapeutics, Inc. Enters into Sponsored Research Agreement with the George Washington University 12.8%
12/26 Form 4 Hoth Therapeutics, Inc. For: Dec 24 Filed by: Hayes Anthony 11.5%
4/24 Voltron Therapeutics, Inc. Announces Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine 8.8%
8/23 Form 8-K Hoth Therapeutics, Inc. For: Aug 19 7.9%
6/11 Biotech Brief: Atopic Dermatitis (Eczema) Revenues Projected to Exceed $6 Billion by 2022 7.4%
4/3 Form S-1 Hoth Therapeutics, Inc. 7.3%
4/22 Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate 30.8%
2/4 Hoth Initiates Preclinical Gene Therapy Program with NC State for the Treatment of Asthma and Allergic Inflammation 16.0%
11/26 Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy 15.9%
6/27 Hoth Therapeutics, Inc. Enters into Sponsored Research Agreement with the George Washington University 12.8%
12/26 Form 4 Hoth Therapeutics, Inc. For: Dec 24 Filed by: Hayes Anthony 11.5%
4/24 Voltron Therapeutics, Inc. Announces Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine 8.8%
8/23 Form 8-K Hoth Therapeutics, Inc. For: Aug 19 7.9%
6/11 Biotech Brief: Atopic Dermatitis (Eczema) Revenues Projected to Exceed $6 Billion by 2022 7.4%
4/3 Form S-1 Hoth Therapeutics, Inc. 7.3%
TOP News Decliners
3/23
Hoth Therapeutics inks deal to develop vaccine for Covid-19 [Seeking Alpha]
-38.3%
3/27 HaloVax™ Announces Agreement with Hoth Therapeutics to Joint Develop a Self-Assembling Vaccine (SAV) to Protect Patients at Risk of Coronavirus (COVID-19) Infection -21.8%
4/23 REMINDER: Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate -19.8%
3/23 Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock -15.8%
7/22 Biotech Brief: Reports Forecast Continued Rise in Revenues for Diabetic Ulcer Treatment Market -14.7%
8/30 Form S-1 Hoth Therapeutics, Inc. -12.0%
3/4 Form SC 13G Hoth Therapeutics, Inc. Filed by: EITNER MATTHEW D. -8.6%
9/6 Hoth Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference -8.5%
10/25 Form 424B3 Hoth Therapeutics, Inc. -7.9%
3/16 Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share -7.7%
3/27 HaloVax™ Announces Agreement with Hoth Therapeutics to Joint Develop a Self-Assembling Vaccine (SAV) to Protect Patients at Risk of Coronavirus (COVID-19) Infection -21.8%
4/23 REMINDER: Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate -19.8%
3/23 Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock -15.8%
7/22 Biotech Brief: Reports Forecast Continued Rise in Revenues for Diabetic Ulcer Treatment Market -14.7%
8/30 Form S-1 Hoth Therapeutics, Inc. -12.0%
3/4 Form SC 13G Hoth Therapeutics, Inc. Filed by: EITNER MATTHEW D. -8.6%
9/6 Hoth Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference -8.5%
10/25 Form 424B3 Hoth Therapeutics, Inc. -7.9%
3/16 Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share -7.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: